The author believes Sivers is a credible small-cap AI optics play with real technology, ecosystem relevance, and early product traction, and that the risk/reward remains attractive despite financial i
The author believes Sivers is a credible small-cap AI optics play with real technology, ecosystem relevance, and early product traction, and that the risk/reward remains attractive despite financial immaturity, with catalysts like a potential US listing.
SIVE
MED
Apr 21, 15:47
"Disclosure: I am long SIVE."
TLDR
Outlier Capital argues that Sivers Semiconductors (SIVE) is one of the most credible small-cap ways to play the AI optical stack, citing real photonics product traction, ecosystem partnerships (POET, Jabil, Marvell/NVIDIA), and a potential Nasdaq dual listing as catalysts. However, the author cautions that the company is still early in its transformation — product revenue is small, cash flow negative, and the stock has already rerated — so further upside depends on execution, not just narrative.
• Sivers has real photonics technology (DFB lasers) used in AI optical interconnects, with growing product revenue and partnerships (POET, Jabil, WIN Semiconductors).
• The supply chain chain (Sivers→POET→Celestial AI→Marvell→NVIDIA) gives the thesis substance, though direct NVIDIA exposure is not confirmed.
• Financials are still immature: most revenue is NRE/development, product sales are small, and cash flow remains negative, but photonics product revenue is inflecting positively.
• A potential Nasdaq dual listing is highlighted as a major bullish catalyst that could expand the investor base and liquidity, but also brings PCAOB audit risks.
• The author is constructive but selective: the stock is no longer cheap, and the next leg requires productization, better financial quality, and capital discipline.
• The author explicitly discloses being long SIVE, indicating a personal conviction in the asymmetric risk/reward over the next 18-24 months.
April 21, 2026 at 15:47